Objetivo The goal of this CRAFT consortium is the generation of a prototype of a new generation of drugs, which are based on the combination of established technologies in the field of protein engineering, DNA-targeting and drug delivery. The combination of the diverse fields of technology is very innovative and a reachable task. As prototype we aim for a double targeted therapeutic compound which is a carcinoma cell specific delivered and carcinoma gene specific in his DNA-methyltransferase activity which can switch the expression of a tumour-associated gene involved in carcinogenesis expressed in 40% of all human tumours, from on to off. Cancer is the second cause of death in the Western world and continues to emerge at an accelerated rate in the developing countries as well. Although progress has been made in the therapy of some types of cancer, the overall survival prognosis with current standard therapy is poor. Therefore, new treatment strategies are needed. The approach we propose here is based on the selective silencing of the epithelial glycoprotein-2 (EGP-2) gene, which is abundantly expressed in a variety of carcinomas, counting for 40% of all cancers. The goal of the proposed method is to selectively silence the EGP-2 gene by targeted methylation of the EGP-2 promoter. The therapeutic compounds we wish to develop consist of a targeted DNA methyltransferase and a targeted delivery system, based on synthetic amphiphiles, specific for EGP-2 positive cells. The targeted DNA-methyltransferase is a covalent complex of a triplex forming oligonucleotide (TFO) and the CpG-specific DNA methyltransferase M.SssI. This TFO-M.SssI conjugate has the potential to methylate a unique CpG site in a genome. Because of the high targeting specificity of the envisaged product, the proposed approach is expected to be free of many negative side effects, and thus can lead to a more effective treatment of a broad-range of cancers. Ámbito científico natural sciencesbiological sciencesgeneticsDNAmedical and health sciencesclinical medicineoncologynatural sciencesbiological sciencesgeneticsgenomesnatural sciencesbiological sciencesbiochemistrybiomoleculesproteinsenzymesnatural sciencesbiological sciencesgeneticsepigenetics Programa(s) FP6-SME - Horizontal research activities involving SMEs: Specific activities covering wider field of research under the Focusing and Integrating Community Research programme 2002-2006. Tema(s) SME-1 - Co-operative Research (all areas of science and technology) Convocatoria de propuestas FP6-2003-SME-1 Consulte otros proyectos de esta convocatoria Régimen de financiación Data not available Coordinador SYNVOLUX THERAPEUTICS BV Aportación de la UE Sin datos Dirección L.J. Zielstraweg 1 GRONINGEN Países Bajos Ver en el mapa Enlaces Sitio web Opens in new window Coste total Sin datos Participantes (5) Ordenar alfabéticamente Ordenar por aportación de la UE Ampliar todo Contraer todo EPIGENOMICS AG Alemania Aportación de la UE Sin datos Dirección Kastanienallee 24 BERLIN Ver en el mapa Enlaces Sitio web Opens in new window Coste total Sin datos MAGYAR TUDOMANYOS AKADEMIA SZEGEDI BIOLOGIAI KOZPONTJA Hungría Aportación de la UE Sin datos Dirección Temesvari krt. 62 SZEGED Ver en el mapa Enlaces Sitio web Opens in new window Coste total Sin datos PRIMM SRL Italia Aportación de la UE Sin datos Dirección VIA OLGETTINA 58 MILANO Ver en el mapa Enlaces Sitio web Opens in new window Coste total Sin datos RHEINISCH-WESTFAELISCHE TECHNISCHE HOCHSCHULE AACHEN Alemania Aportación de la UE Sin datos Dirección Templergraben 55 AACHEN Ver en el mapa Enlaces Sitio web Opens in new window Coste total Sin datos RIJKSUNIVERSITEIT GRONINGEN Países Bajos Aportación de la UE Sin datos Dirección Broerstraat 5 GRONINGEN Ver en el mapa Enlaces Sitio web Opens in new window Coste total Sin datos
